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Background: Inﬂuenza is a common viral respiratory
infection that is associated with signiﬁcant morbidity.
Oseltamivir (Tamiﬂu) is a neuraminidase inhibitor—a
new class of antiviral treatment for inﬂuenza where efﬁ-
cacy and safety has been established but cost-effectiveness
is unknown.
Methods: A decision analytic model was used to estimate
the costs and effectiveness of two treatment scenarios 
for empiric management of otherwise healthy nonelderly
patients, presenting with inﬂuenza-like illness (ILI) to
primary care physicians in Canada: 1) where oseltamivir
is reimbursed and on formulary for prescription; and 2)
where oseltamivir is not on formulary. Outcomes are
inﬂuenza-days averted and quality-adjusted life-years
(QALYs) gained. Effectiveness, utility, and pneumonia
complication risk estimates are by pooled analysis of
patient-level data from four clinical trials. Unit cost infor-
mation (Canadian dollars) was obtained from published
sources in Ontario. Probabilistic sensitivity analysis was
conducted using Monte Carlo simulation.
Results: Of 2288 patients randomized, inﬂuenza was con-
ﬁrmed in 1575 (69%) and oseltamivir treatment reduced
the mean time to symptom alleviation by 1.08 days (95%
conﬁdence interval [CI] 0.58–1.59). Infected patients
treated with oseltamivir had higher utility scores (quality
of life) than placebo patients over the 7 days of follow-
up (P < .05). Cost per inﬂuenza-day averted with
oseltamivir on formulary is $49 (95% CI 31–107) and
the cost per QALY is $57,863 (95% CI $48,919–
$70,149). Results are sensitive to the percentage of
patients presenting to their physician beyond 48 hours
from symptom onset who get oseltamivir and the preva-
lence of inﬂuenza among patients presenting with ILI.
Conclusions: Oseltamivir for treatment of patients with
ILI is potentially cost-effective if clinical diagnostic speci-
ﬁcity for inﬂuenza observed in clinical trials is applicable
to routine practice. More population-based information
on the prevalence of inﬂuenza among early (<48 hours)
presenters with ILI would be valuable.
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Inﬂuenza is a common viral respiratory infection
that affects one in six people annually [1] and can
lead to serious complications including pneumonia
and hospitalization. Each year in Canada, inﬂuenza
results in 75,000 hospitalizations and 6,000 deaths
[1]. Vaccination is 70% effective in preventing sero-
logically conﬁrmed inﬂuenza in healthy adults [2]
and 50% to 60% effective in preventing complica-
tions in high-risk individuals [3]. Although it is the
most important method for prevention, vaccination
may not always reduce clinical symptoms and efﬁ-
cacy may vary depending on how well matched the
circulating inﬂuenza virus is to the antigens in the
vaccine. Furthermore, the population effectiveness
and cost-effectiveness of vaccination are dependent
on compliance.
Although the antiviral agent amantadine is
licensed for the prevention and treatment of
inﬂuenza [4], its use is limited by frequent side
effects, the development of resistance, and the fact
that it is only active against inﬂuenza A [5]. Riman-
tadine is not approved for use in Canada. The 
neuraminidase inhibitors oseltamivir (Tamiﬂu,
Hoffmann-La Roche Inc., Nutley, NJ) and
zanamivir (Relenza, GlaxoSmithKline, Research
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Triangle Park, NC) are a new class of inﬂuenza
treatment that bind to neuraminidase proteins
found on the surface of both inﬂuenza A and B
viruses. The neuraminidase inhibitors have been
evaluated primarily for treatment of nonelderly,
healthy adults and have been shown to reduce 
clinical symptoms by approximately 1 day [6].
Oseltamivir is approved for treatment of inﬂuenza
in adults who have been symptomatic for no more
than 2 days, and a 5-day course of one 75-mg
capsule twice a day, including dispensing fee and
pharmacy mark-up, would cost a Canadian provin-
cial government health care payer CAN$50.31.
Given that the focus of our study is treatment of
nonelderly patients who will mostly not be covered
by provincial drug plans, the viewpoint of our study
is essentially a mixture of private and public health-
care payers, although we frame the problem in 
the usual context of value for money to a universal
public health care payer. This study viewpoint is
consistent with two recent studies of zanamivir by
the National Institute for Clinical Effectiveness
(NICE) [7] and the Canadian Coordinating Ofﬁce
for Health Technology Assessment (CCOHTA) [8].
We use techniques of decision analysis and related
mathematical modeling to estimate both the cost-
effectiveness (cost per inﬂuenza-day averted) and
the cost utility (cost per quality-adjusted life-year
[QALY]) of a scenario where oseltamivir is on 
formulary compared to off formulary for otherwise
healthy adults who present with inﬂuenza-like
illness (ILI) and are managed empirically by their
physician. In creating our cost-effectiveness model,
we also present patient-level pooled analysis of data
on effectiveness, utility, and secondary inﬂuenza
complications from the four randomized trials of
oseltamivir in healthy adults.
Methods
Overview of Modeling Framework
The framework for our model is presented as a deci-
sion tree in Fig. 1. Consistent with the inclusion and
exclusion criteria of the oseltamivir clinical trials,
we assume a cohort of otherwise healthy adults,
aged 16 to 64 years, with no comorbid conditions
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Figure 1 Decision tree for patients presenting with ILI and comparing two scenarios: (A) oseltamivir on formulary and (B) oseltamivir not
on formulary.
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and with no prior inﬂuenza vaccination. The
assumed decision context is that inﬂuenza virus is
circulating in the community and patients present
to their physician with ILI where they would be
treated empirically—that is, without conﬁrmatory
testing for viral infection. Over a 7-day time
horizon, we compare two treatment scenarios for a
patient presenting with ILI: 1) where oseltamivir is
on formulary and can be prescribed; and 2) where
oseltamivir is not on formulary.
The model is structured in three parts: Part 1 is
the probability that a patient presenting with ILI,
when the inﬂuenza virus is circulating, is infected
with inﬂuenza. Oseltamivir is effective in persons
who have inﬂuenza, and although rapid diagnostic
tests for the inﬂuenza virus are available, our model
reﬂects current practice of empiric management
based on clinical signs and symptoms. In part 2 of
the model, we include two related probabilities: 1)
a patient with ILI presents within 48 hours of
symptom onset; and 2) a patient who presents after
48 hours will receive oseltamivir. Also in part 2 of
the model, we assume whether oseltamivir is on for-
mulary or not, of those patients that do not receive
it will be managed with either an antibiotic, inap-
propriately for a viral infection but based on non-
speciﬁc diagnosis, or no drug therapy. Finally, part
3 of the model focuses on the presence or absence
of secondary complications due to inﬂuenza, specif-
ically, the excess risk and cost of pneumonia.
Data available from four trials. Four randomized
controlled trials have compared oseltamivir (75 mg
orally twice a day for 5 days) with placebo in
healthy adults. We conducted a pooled analysis of
patient-level data from the two trials published by
Nicholson et al. [9] and Treanor et al. [10] plus the
two unpublished trials, protocols WV15730 and
M76001, which have not yet been published. Each
of the four trials was conducted in otherwise healthy
adults aged less than 65 years with no prior
inﬂuenza vaccination who presented during
inﬂuenza season, within 48 hours of symptom onset,
with ILI deﬁned as fever of at least 38°C, with at
least one respiratory symptom (cough, sore throat,
or nasal symptom) and at least one constitutional
symptom (headache, malaise, myalgia, sweats or
chills, or fatigue). The trial populations and in-
ﬂuenza infection data are summarized in Table 1.
Effectiveness. On each of the 7 days after ran-
domization, patients reported two aspects of
outcome: the presence and severity (none, mild,
moderate, severe) of seven inﬂuenza symptoms:
cough, nasal obstruction, sore throat, fatigue,
headache, myalgia, and feverishness. The primary
trial end point was the time to resolution of illness,
deﬁned as the time interval between randomization
and when all seven symptoms were rated as being
“none or mild.” We calculate the mean time to
illness resolution using the method of Kaplan and
Meier [11], for the trials separately and pooled, and
take the difference in means between the treatment
groups as our effectiveness measure of “inﬂuenza-
days averted” due to oseltamivir treatment.
Utility. The second outcome measure is a visual
analog scale (VAS) that was completed by patients
on each of the 7 days. The VAS was a 10-cm line
with 0 labeled as being “worst possible health” and
10 as “normal health.” Similar to the use of the VAS
component in the Euroqol utility measure [12], the
Table 1 Sample size, inﬂuenza infection status, and risk of secondary inﬂuenza complications in four oseltamivir trials among
otherwise healthy adults aged less than 65 years
Secondary complications among 
patients with conﬁrmed inﬂuenza:
Number (%) with
Protocol Treatments Total patients inﬂuenza infection All complications* Pneumonia*
WV15670 [10] Placebo 238 160 (67) 10 (6.3) 1 (0.6)
75mg oseltamivir bid 242 157 (65) 9 (5.7) 0 (0)
WV15671 [9] Placebo 209 129 (62) 20 (15.5) 1 (0.7)
75mg oseltamivir bid 211 124 (59) 11 (8.9) 0 (0)
WV15730 Placebo 26 19 (73) 1 (5.3) 1 (5.0)
75mg oseltamivir bid 31 19 (62) 2 (10.5) 0 (0)
M76001 Placebo 447 331 (74) 30 (9.1) 6 (1.8)
75mg oseltamivir bid 884 636 (72) 50 (7.9) 2 (0.3)
Pooled Placebo 920 639 (69) 63 (9.8) 9 (1.4)
75mg oseltamivir bid 1368 936 (68) 76 (8.1) 2 (0.2)
Pooled odds ratio 0.80 0.15
(95% CI) (0.55–1.14) (0.02–0.73)
*N (%).
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VAS permits a global estimate of the value or utility
the patients assigned to their health to each of the
7 days. Normalizing this 0 to 10 score into a 0 to
1 interval we then used these weights as quality-
adjustment factors for each of the 7 days and cal-
culated QALYs as a measure of outcome for
cost-utility analysis [13].
Secondary complications of inﬂuenza. Common
secondary complications of inﬂuenza are otitis
media, bronchitis, sinusitis, and pneumonia. The
frequency of these complications was collected in
the trials and we estimated pooled relative odds to
determine if oseltamivir treatment is associated with
reduced risk of complication for inclusion in our
model.
Model probabilities not available from the
trial. Four probabilities required for the model
were not available from the trials: 1) the probabil-
ity of hospitalization among persons with a sec-
ondary complication of inﬂuenza was from a recent
study by Minogue et al. [14] who showed that
approximately 7.5% of patients with community-
acquired pneumonia were subsequently hospital-
ized within 30 days; 2) the probability of a patient
presenting with ILI receiving an antibiotic was from
the study by Monto et al. [15] on claims data from
a large US health insurance database that covered
patients from the New England region from 1995
to 1997 and where 36.5% of noncomplicated 15-
to 64-year-old patients with ILI were prescribed an
antibiotic; 3) the probability of a patient with ILI
presenting to their physician within 48 hours of
symptom onset was an assumption informed by
market research data (J. Adams, Hoffman-LaRoche
Ltd., personal communication May 2001) of 50%
and we vary this in the sensitivity analysis; and 
(4) for the probability of a patient presenting
>48 hours receiving oseltamivir is unknown and
assumed to be 0% (full compliance with labeling)
and we vary this in sensitivity analysis. The model
probabilities and distributions are presented in
Table 2.
Price weights. Drug prices for antibiotics are from
the Ontario Drug Beneﬁt program [16]. All pre-
scription costs include pharmacy mark-up (10%).
The cost of a 5-day course of oseltamivir, including
pharmacy mark-up and dispensing fee was $50.31.
The typical mix of antibiotics prescribed for ILI was
identiﬁed from Intercontinental Medical Statistics
[17] and based on the utilization-weighted mix of
antibiotic prescriptions written by a panel of physi-
cians and where inﬂuenza is mentioned as the
reason for the prescription. Including dispensing fee
and pharmacy mark-up this typical antibiotic script
was estimated to be $19.57.
Physician fees for visits were obtained from the
Ontario Schedule of Beneﬁts for insured medical
services [18]. We assumed that physicians would
bill a general assessment ($28.10) for the initial
patient visit and bill a minor assessment ($16.25)
for any resulting secondary complications. Finally,
the cost of pneumonia hospitalization was esti-
mated to be $2852. This cost was obtained from 
a hospital in southwestern Ontario participating in
the Ontario Case Costing Project based on all hos-
pitalized cases during 1999 [19].
Cost-effectiveness and cost-utility analysis.
Using the probabilities described above, we calcu-
lated expected values for cost per patient, days with
symptoms per inﬂuenza episode, and QALYs. If 
the oseltamivir strategy was both more effective 
and more costly, we calculated incremental cost-
effectiveness as the cost per inﬂuenza-day averted
and incremental cost utility as the cost per QALY.
Analysis of uncertainty and variability. To 
quantify the precision of our cost-effectiveness 
and cost-utility estimates, we conducted probabilis-
Table 2 Model probabilities and distributions
Distributions for 
Number with Number with Total, Expected value, Monte Carlo 
Probability (P) ofmodel parameter event, a no event, b a + b a/(a + b) simulation, Beta (a, b) Source
P (any complication Ω no oseltamivir)* 63 576 639 0.09859 Beta (63, 576) Pooled trials
P (any complication Ω oseltamivir) 76 860 936 0.08119 Beta (76, 860) Pooled trials 
P (pneumonia Ω complication Ω no oseltamivir) 9 54 63 0.14286 Beta (9, 54) Pooled trials
P (pneumonia Ω complication Ω oseltamivir) 2 74 76 0.02632 Beta (2, 74) Pooled trials
P (hospitalization Ω pneumonia) 71 873 944 0.07521 Beta (71, 873) Minogue et al. [14]
P (antibiotic)† 3335 5790 9125 0.36547 Beta (3335, 5790) Monto et al. [26]
P (inﬂuenza infection) 1575 713 2288 0.68837 Beta (1575, 713) Pooled trials
*The symbol “|” means conditional upon. Hence, this is the probability of complication given that the patient was not receiving oseltamivir.
†For scenario of oseltamivir not on formulary.
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tic sensitivity analysis by Monte Carlo simulation
with 1000 iterations [20,21]. Simulation of the joint
density of costs and outcomes permits the determi-
nation of 95% conﬁdence intervals (CIs) for the
incremental ratios. Two-way sensitivity analysis
was conducted for two key parameters in the
model: 1) the prevalence of inﬂuenza among
patients presenting with ILI within 48 hours; and 
2) the proportion of patients presenting beyond
48 hours who get oseltamivir.
Results
Pooled Analysis Sample
The four trials for the pooled analyses are sum-
marized in Table 1. A total of 2288 patients 
aged 16 to 64 years who presented within 48 hours
of symptom onset were available for pooled 
analysis, of which 1368 (60%) received oseltamivir
and 920 (40%) placebo. A total of 1575 (69%)
tested positive for the presence of inﬂuenza 
virus, by culture or serology, subsequent to 
randomization.
Effectiveness
For the 632 patients with conﬁrmed inﬂuenza 
who received placebo, the mean time to symptom
alleviation was 6.83 days (95% CI 6.43–7.21) 
compared to 5.75 days (95% CI 5.44–6.02) for
patients receiving oseltamivir (Table 3), a differ-
ence of 1.08 days (95% CI 0.58–1.59). Among 
the 31% of patients without conﬁrmed inﬂuenza,
there was no treatment effect associated with
oseltamivir.
Secondary Complications
There was no statistically signiﬁcant difference in
the risk of all complications with pooled relative
odds of 0.80 (95% CI 0.55–1.14) (Table 1).
However, the risk of pneumonia was signiﬁcantly
lower among patients receiving oseltamivir (2/936)
at 0.2% than placebo (9/639) at 1.4%, for a pooled
relative odds of 0.15 (95% CI 0.02–0.73).
Utility and QALYs
Complete data on VAS utility scores for each of the
7 study days were available from 2207 of the 2288
patients, and there was no evidence that the missing
data for 81 patients (3.5%) was correlated with
treatment assignment or otherwise informative.
Mean health state utility scores are presented in
Table 4 and plotted in Fig. 2. For patients with con-
ﬁrmed inﬂuenza (Fig. 2A), the utility scores for days
2 through 7 are signiﬁcantly higher among patients
receiving oseltamivir and the cumulative utility
scores are 4.24 quality-adjusted life-days (QALDs)
with placebo versus 4.59 days with oseltamivir.
Converting to QALYs, and weighting by infection
Table 3 Pooled analysis of time-to-alleviation of all symptoms for patients with and without inﬂuenza infection
Time (days) to symptom alleviation
Protocol Treatment N Mean (95% CI) Median
Patients with inﬂuenza infection
WV15670 Placebo 160 6.60 (5.89, 7.43) 5
Oseltamivir 156 5.34 (4.70, 5.93) 4
WV15671 Placebo 128 5.74 (5.08, 6.50) 5
Oseltamivir 121 4.29 (3.74, 4.95) 3
WV15730 Placebo 19 6.05 (5.14, 6.96) 6
Oseltamivir 19 5.05 (2.90, 7.21) 4
M76001 Placebo 325 7.14 (6.59, 7.67) 6
Oseltamivir 616 6.09 (5.70, 6.43) 4
All pooled Placebo 632 6.83 (6.43, 7.21) 5
Oseltamivir 912 5.75 (5.44, 6.02) 4
Patients without inﬂuenza infection
WV15670 Placebo 74 6.25 (5.18, 7.16) 5
Oseltamivir 83 6.78 (5.55, 8.07) 6
WV15671 Placebo 72 5.69 (4.63, 6.75) 4
Oseltamivir 83 5.44 (4.50, 6.37) 4
WV15730 Placebo 7 2.14 (1.13, 3.25) 2
Oseltamivir 12 4.81 (2.98, 6.64) 4
M76001 Placebo 110 7.27 (5.98, 8.61) 5
Oseltamivir 232 6.98 (6.22, 7.82) 5
All pooled Placebo 263 6.97 (6.10, 7.81) 5
Oseltamivir 410 6.64 (6.09, 7.24) 5
Note: Example calculations for “days with ﬂu symptoms” in base-case cost-effectiveness as infection-weighted average: 1) oseltamivir not on formulary,
0.69 (6.83) + 0.31 (6.97) = 6.88 ﬂu days; or 2) oseltamivir on formulary, 0.69 (0.5 ¥ 6.83 + 0.5 ¥ 5.75) + 0.31 (0.5 ¥ 6.97 + 0.5 ¥ 6.64) = 6.45 ﬂu days.
121Oseltamivir Cost-Effectiveness in Inﬂuenza
status, yields 0.01173 for the oseltamivir not on for-
mulary scenario and 0.01208 for oseltamivir on for-
mulary. Contrasting Fig. 2A and B it is also clear
that the treatment effect of oseltamivir on health
state utility is conﬁned to those patients with
inﬂuenza infection.
Cost-Effectiveness and Cost Utility
Expected costs, effects, and incremental cost-
effectiveness and cost utility are presented in
Table 5. For a given episode of ILI, the cost per
patient with oseltamivir available for prescription is
$60.22 compared to $39.72 if oseltamivir is not
available, which gives an additional cost per patient
of $20.50. This additional cost “buys” an expected
reduction in days with inﬂuenza of 0.42, from 6.88
to 6.45 days. Using the data on utility scores from
Table 4 to weight days by their severity, the gain in
QALDs is 0.13, the difference being 4.41 QALDs
with oseltamivir to 4.28 without. Expressed as
QALYs, this is 0.01208 QALYs with oseltamivir
available and 0.01173 when not available, for a
gain in QALYs of 0.00035. Combining the differ-
ences in costs and outcomes, the incremental 
cost-effectiveness of oseltamivir is $48.52 per
inﬂuenza-day averted (95% CI $30.72–$107.32),
and incremental cost utility is $57,863 per QALY
(95% CI $48,919–$70,149).
Uncertainty and Variability in Cost-Effectiveness and
Cost Utility
The precision of the incremental cost-effectiveness
and cost-utility ratios are represented by the 95%
CIs from the probabilistic sensitivity analysis by
Monte Carlo simulation. In addition, for parameter
estimates that were uncertain but where evidence on
prior probability distributions was limited, we con-
ducted several “traditional” deterministic sensitiv-









































Table 4 Mean health state utility scores (visual analog scale) from pooled oseltamivir trials (0 = worst possible health; 1 =
normal health)
Patients with ﬂu infection Patients without ﬂu infection
Placebo Oseltamivir Placebo Oseltamivir
Day n Mean SEM Mean SEM Mean SEM Mean SEM
1 630 0.40 0.011 0.42 0.090 0.40 0.016 0.42
2 629 0.44 0.008 0.50 0.007 0.48 0.013 0.49
3 621 0.54 0.008 0.61 0.006 0.58 0.013 0.59 0.011
4 617 0.64 0.008 0.69 0.006 0.65 0.013 0.66 0.011
5 615 0.70 0.008 0.75 0.006 0.71 0.013 0.72 0.010
6 605 0.75 0.008 0.79 0.006 0.76 0.013 0.76 0.010
7 601 0.79 0.007 0.82 0.006 0.78 0.013 0.79 0.010
SUM (QALDs) 4.24 4.59 4.36 4.43
Note: Example calculations for QALYs:We need the infection-weighted QALD means adjusted to annual equivalents as follows: 1) oseltamivir not on formulary,
0.69 (4.24) + 0.31 (4.36) = 4.28 QALDs or (∏365) = 0.01173 QALYs; or 2) oseltamivir on formulary, 0.69 (0.5 ¥ 4.24 + 0.5 ¥ 4.59) + 0.31
(0.5 ¥ 4.36 + 0.5 ¥ 4.43) = 4.41 QALDs or (∏365) = 0.01208 QALYs.
Figure 2 Mean (95% CI) utility scores from visual analog scale for study days 1 to 7 (0 = worst possible health; 1 = normal health). (A) Patients
with inﬂuenza: () placebo (n = 630); () oseltamivir (n = 908). (B) Patients without inﬂuenza infection: () placebo (n = 262); () oseltamivir
(n = 407).
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ity analyses. The most informative is the two-way
analysis shown in Fig. 3 where cost per QALY
varies as two key model parameters are varied
simultaneously: 1) the prevalence of inﬂuenza
among patients presenting with ILI; and 2) the per-
centage of patients presenting “late” (>48 hours)
who receive oseltamivir inappropriately. Lowering
the inﬂuenza prevalence from 69% to 50%
increases the cost per QALY to $73,309, and low-
ering prevalence to 25% increases cost per QALY
to $112,867. Increasing the percentage of late ILI
presenters receiving oseltamivir from 0% to 50%
raises the cost per QALY to $88,325. Finally, Fig. 3
permits both model parameters to be varied
together: for example, if inﬂuenza prevalence
among ILI presenters is only 25% and 50% of late
presenters receive oseltamivir, the cost per QALY is
$170,370.
Discussion
Using techniques for evidence synthesis from clini-
cal trials and other sources, we estimate that the
cost per inﬂuenza day averted with oseltamivir on
formulary is $48.52 (95% CI $30.72–$107.32) and
the cost per QALY is $57,863 (95% CI $48,919–
$70,149). However, our study also shows that
results are sensitive to assumed values for two key
parameters: the prevalence of inﬂuenza among
patients presenting with ILI and the percentage 
of patients who present late (>48 hours from
symptom onset) who receive oseltamivir inappro-
priately. Our study also reports new patient-level
pooled clinical trial data on health state utility,
which demonstrates signiﬁcant improvement in
quality of life with oseltamivir over 7 days of
follow-up.
Table 5 Costs and effects of QALDs and QALYs for patients presenting with ILI
Cost $ per Days with
Scenarios patient ﬂu symptoms* QALDs† QALY†
(1) Oseltamivir not on formulary 39.72 6.88 4.28 0.01173
(2) Oseltamivir on formulary 60.22 6.45 4.41 0.01208
Difference (2) – (1) 20.50 0.42 0.13 0.00035
Incremental
Cost per Flu day averted* 48.52 95% CI 30.72–107.32
Cost per QALY* 57,863 95% CI 48,919–70,149
Note: column entries and ratios are not exact due to rounding; to full precision the cost per QALY calculation is $20.495847/0.00035421 = $57,863 per QALY.
*For calculation see footnote of Table 3






















Probability of oseltamivir 
treatment after 48h (base = 0)
Base case
($58K/QALY)
Figure 3 Two-way sensitivity analysis of cost per QALY by probability of inﬂuenza infection among patients with ILI and probability of receiv-
ing oseltamivir after 48 hours from symptom onset.
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We are not aware of any previous study of the
cost-effectiveness of oseltamivir in the treatment of
inﬂuenza, but there are three studies on the cost-
effectiveness of zanamivir (Relenza). The ﬁrst of
these studies by Mauskopf et al. [22] is not directly
comparable with ours because it focuses on high-
risk populations (elderly) and is based on a sub-
group analysis from one randomized trial. More
directly comparable with our work are the technol-
ogy assessments of zanamivir in healthy adult pop-
ulations by the NICE in the United Kingdom [7,23]
and the CCOHTA in Canada [8]. The NICE report
estimates cost per QALY under two assumptions of
inﬂuenza prevalence in patients presenting with ILI:
with 34% prevalence they estimate $85,000 per
QALY and with 14% prevalence they estimate
$353,000 per QALY (dollar conversions reported in
the CCOHTA study [8]). Similarly, the CCOHTA
report—which borrows heavily from the NICE
report on evidence synthesis and assumptions—esti-
mates $77,000 per QALY at 35% inﬂuenza preva-
lence and a $195,000 per QALY at a 14%
prevalence.
There are two key points of discussion when
comparing the results of our study with the NICE
and CCOHTA estimates: the validity of the utility
data and the assumed inﬂuenza prevalence among
ILI presenters. Our study summarizes health state
utility data from 2207 trial patients who completed
a VAS measurement daily for 7 days. The utility
weighting used in the NICE report was an assump-
tion by the authors of the associated utility decre-
ment for the 1-day difference in inﬂuenza duration;
it was justiﬁed only on the basis of agreement with
the earlier utility assumption used by Mauskopf et
al. [22]. The CCOHTA study based their utility esti-
mate on a small (n = 11) sample of convenience. As
we have shown, the effect of oseltamivir treatment
on quality of life is a measurable and signiﬁcant
parameter of outcome, and this utility value has not
been shown and incorporated in the previous
models.
The key difference between our model and that
of NICE and CCOHTA is the assumed prevalence
of inﬂuenza among ILI presenters. As conﬁrmation,
we ran our model with a 34% inﬂuenza prevalence,
which yields an estimate of $95,000 per QALY,
broadly similar to the $85,000 per QALY from the
NICE report. In discussing the merits of different
data sources for this parameter value, it is instruc-
tive to begin with a precise deﬁnition: we require
the prevalence of conﬁrmed inﬂuenza among
patients presenting with ILI within 48 hours of
symptom onset when inﬂuenza is circulating in the
community (“ﬂu season”). Our argument is that 
the current best estimate of this parameter is from
the neuraminidase inhibitor trials; this is a value of
69% from the oseltamivir trials in our study and
66% from the zanamivir trials [24]. These trial-
based rates of inﬂuenza prevalence among ILI
patients were conﬁrmed by a population-based
study in Canada where Boivin et al. [27] found a
72% prevalence of inﬂuenza (conﬁrmed via sub-
sequent laboratory testing) among 100 patients
with ILI deﬁned as fever >37.8°C plus two of 
four symptoms: cough, myalgia, sore throat, and
headache. Although a recent study by Govaert et al.
[25] in the Netherlands showed a lower positive
predictive value of 35% for clinical diagnosis in
primary care with patients aged over 60 years, 
the relevance of this ﬁnding to the evaluation of
neuraminidase inhibitors has been questioned by
Monto et al. [26] for two reasons: 1) the study was
not restricted to patients who presented to a physi-
cian early in the course of their illness; and 2) it was
not conducted when inﬂuenza was circulating in the
community.
The primary data source for the lower NICE
assumption of 14% inﬂuenza prevalence among ILI
presenters is virologic surveillance programs by
public health laboratories [7,23]. Speciﬁcally, they
describe that the data are laboratory-conﬁrmed
cases of inﬂuenza among patients presenting within
5 days of ILI symptom onset, which is deﬁned as
acute respiratory tract infection with fever. By def-
inition, this is not the prevalence of inﬂuenza among
patients presenting within 48 hours of ILI symptom
onset, which is the approved indication for
oseltamivir and the focus of our study. Although
more population-based data on inﬂuenza preva-
lence among early (<48 hours) ILI presenters during
inﬂuenza season would be helpful, it is clear from
Fig. 3 that when this parameter is greater than 50%
cost-effectiveness does not vary widely.
A limitation of our current analysis is that we
have excluded the gains in work time that would
accrue from earlier termination of inﬂuenza among
patients treated with oseltamivir. This gain in pro-
ductive time was conﬁrmed in the Cochrane review
[6] of neuraminidase inhibitors. To the extent that
we have not included this parameter of beneﬁt our
analysis represents an underestimate of the beneﬁt
in relation to cost of oseltamivir treatment. A poten-
tial bias in the other direction is that we have not
explicitly included the adverse effect of nausea and
vomiting, which was seen more frequently in those
treated with oseltamivir. However, our assumption
was that any reduced quality of life associated with
124 O’Brien et al.
this adverse effect would be captured by the daily
utility measurement.
In conclusion, we have shown that oseltamivir
generates additional beneﬁts at higher cost and at a
rate of $57,863 per QALY. This is potentially in the
“fundable zone” for new health technologies
between $20,000 and $100,000 per QALY as spec-
iﬁed by Laupacis et al. [28] and lower than the
benchmark of US$50,000 per QALY often cited in
the United States [29]. However, there remain key
uncertainties for payers, particularly regarding the
speciﬁcity of clinical diagnosis for inﬂuenza and tar-
geting the use of oseltamivir in patients where it will
be most efﬁcacious and cost-effective. An important
direction for future work is an assessment of 
the cost-effectiveness of rapid diagnostic tests for
inﬂuenza as a means of better targeting use of neu-
raminidase inhibitors to patients with inﬂuenza.
Some of this work has already begun with the recent
model by Blitz et al. [30] where the decision to treat,
test, or prescribe treatment empirically is crucially
dependent on the probability of inﬂuenza and the
monetary value of the treatment beneﬁt.
This study was funded by Hoffmann-La Roche Ltd., as a
grant to the Center for Evaluation of Medicines.
References
1 Canadian Consensus Conference on Inﬂuenza.
Can Commun Dis Rep 1993;19:136–46.
2 Demicheli V, Rivetti D, Deeks JJ, Jefferson TO.
Vaccines for preventing inﬂuenza in healthy adults
(Cochrane Review). In: The Cochrane Library.
Issue 2, 2001. Oxford: Update Software.
3 Gross PA, Hermogenes AW, Sacks HS, et al. The
efﬁcacy of inﬂuenza vaccine in elderly persons: 
a metaanalysis and review of the literature. Ann
Intern Med 1995;123:518–27.
4 Jefferson TO, Demicheli V, Deeks JJ, Rivetti D.
Amantadine and rimantadine for preventing and
treating inﬂuenza A in adults (Cochrane Review).
In: The Cochrane Library. Issue 2, 2001. Oxford:
Update Software.
5 National Advisory Committee on Immunization.
Statement on inﬂuenza vaccination for the
1999–2000 season. Can Commun Dis Rep 1999;
25:1–16.
6 Jefferson T, Dimicheli V, Deeks J, Rivetti D. Neu-
raminidase inhibitors for preventing and treating
inﬂuenza in healthy adults (Cochrane Review). In:
The Cochrane Library. Issue 2, 2001. Oxford:
Update Software.
7 National Institute of Clinical Excellence.
Zanamivir for the Treatment of Inﬂuenza in
Adults. London: The Institute, 2000.
8 Brady B, McAuley L, Shukla VK. Economic 
Evaluation of Zanamivir for the Treatment of
Inﬂuenza. Ottawa: Canadian Coordinating Ofﬁce
of Health Technology Assessment (CCOHTA),
2001.
9 Nicholson KG, Aoki FY, Osterhaus ADME, et al.
Efﬁcacy and safety of oseltamivir in treatment 
of acute inﬂuenza: a randomized controlled trial.
Lancet 2000;355:1845–50.
10 Treanor JJ, Hayden FG, Vrooman PS, et al. Efﬁ-
cacy and safety of the oral neuraminidase inhibitor
oseltamivir in testing acute inﬂuenza: a ran-
domised controlled trial. JAMA 2000;283:1024.
11 Kaplan EL, Meier P. Nonparametric estimation
from incomplete observations. J Am Stat Assoc
1958;53:457–81.
12 Kind P, Dolan P, Gudex C, Williams A. Variations
in population health status: results from a United
Kingdom national questionnaire survey. BMJ
1998;316:736–41.
13 Drummond MF, O’Brien BJ, Stoddart GL, 
Torrance GW. Methods for Economic Evaluation
of Health Care Programmes (2nd ed.). Oxford:
Oxford University Press, 1997.
14 Minogue MF, Coley CM, Fine MJ, et al. Patients
hospitalized after initial outpatient treatment for
community-acquired pneumonia. Ann Emerg Med
1998;31:376–80.
15 Monto A, Npalkov P, Wegmuller Y. Medical
Resources Utilization for Inﬂuenza and Inﬂuenza-
Related Complications in a Large Health Insur-
ance Plan. Buenos Aries: International Congress
for Infectious Diseases, 2000.
16 Ministry of Health. Drug Beneﬁt Formulary: 
Comparative Drug Index (Vol. 36). Toronto: Pub-
lications Ontario, 1999.
17 Intercontinental Medical Statistics. Compuscript
Database: Prescriptions with a Flu Diagnosis from
October 1998–September 1999. Pointe-Claire:
IMS, 1999.
18 Ontario Ministry of Health. Schedule of Beneﬁts:
Physician Services under the Health Insurance 
Act, February 1, 1998. Toronto: Queen’s Printer,
1999.
19 Ontario Case Cost Project (OCCP): Ontario Guide
to Case Costing (Version 1.1). Ottawa: Ontario
Case Cost Project, 1995 Sep.
20 Briggs AH. Handling uncertainty in cost-effective
models. Pharmacoeconmics 2000;17:479–500.
21 Doubilet P, Begg CB, Weinstein MC, et al. Proba-
bilistic sensitivity analysis using Monte Carlo 
simulation: a practical approach. Med Decis
Making 1985;5:157–77.
22 Mauskopf JA, Cates SC, Grifﬁn AD, et al. Cost
effectiveness of Zanamivir for the treatment of
inﬂuenza in a high-risk population in Australia.
Pharmacoeconomics 2000;17:611–20.
23 National Institute of Clinical Excellence.
Zanamivir for the Treatment of Inﬂuenza in
125Oseltamivir Cost-Effectiveness in Inﬂuenza
Adults: Supplement to the Assessment Report.
London: The Institute, 2000.
24 Monto AS, Gravenstein S, Elliott M, et al. Clini-
cal signs and symptoms predicting inﬂuenza infec-
tion. Arch Intern Med 2000;160:3243–7.
25 Govaert ThM, Dinant GL, Aretz K, Knottnerus
JA. The predictive value of inﬂuenza symptoma-
tology in elderly people. Family Pract 1998;15:
16–22.
26 Monto AS, Gravenstein S, Elliott M, Colopy M,
et al. Signs and symptoms predicting inﬂuenza
infection (reply). Arch Intern Med 2001;161:
1351–2.
27 Boivin G, Hardy I, Tellier G, Maziade J. Predict-
ing inﬂuenza infections during epidemics with use
of a clinical case deﬁnition. Clin Infect Dis 2000;
31:1166–9.
28 Laupacis A, Feeny D, Detsky AS, Tugwell P. How
attractive does a new technology have to warrant
adoption and utilization? Tentative guidelines 
for using clinical and economic evaluations. CMAJ
1992;146:473–81.
29 Hirth RA, Chernew ME, Miller E, et al. Willing-
ness to pay for quality-adjusted life year. in search
of a standard. Med Decis Making 2000;20:
332–42.
30 Blitz SG, Cram P, Chernew ME, et al. Diagnostic
testing or empirical neuraminidase inhibitor
therapy for patients with inﬂuenza-like illness:
what a difference a day makes. Am J Manag Care
2002;8:221–7.
